期刊
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
卷 23, 期 4, 页码 297-313出版社
TAYLOR & FRANCIS AS
DOI: 10.1080/14737159.2023.2195553
关键词
Biomarker; lipidomics; metabolomics; metabolism; prostate cancer; renal cell carcinoma
类别
Lipidomics studies the role of lipids in cancer development, with a focus on renal cell carcinoma and prostate cancer. Aberrant lipid metabolism may serve as biomarkers and therapeutic targets, and specific metabolite profiles can be used to track tumor progression in urological malignancies.
IntroductionLipidomics focuses on the in-depth analysis of lipids, which are crucial macromolecules involved in a wide range of metabolic pathways. The increased intracellular accumulation of different classes of lipids in renal cell carcinoma (RCC) and prostate cancer (PCa) cells may be caused by elevated absorption or by increased de novo lipogenesis as a consequence of lipid metabolism reprogramming. The involvement of cholesterol metabolism in cancer's aberrant pathways has also been demonstrated.Areas coveredThis review provides an update on the most important lipidomics studies and applications in RCC and PCa, with a particular focus on how knowledge of aberrant lipid pathways may be used to identify biomarkers and novel therapeutic targets. In addition, the application of this methodologies have led to novel cancer subtypes identification and patient's risk stratification. Tracking tumor progression using specific biofluid metabolite profiles offers a huge translational opportunity for urological malignancies.Expert opinionLipidomics is a promising branch of 'omics' approach and should include in next decade new standardized analysis methods and randomized clinical trials in order to reach the aim to use this high-throughput technique in patient-tailored therapy perspective.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据